Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of ciltacabtagene autoleucel versus PVd or DPd in lenalidomide-refractory relapsed multiple myeloma
MOH_2020-06-08_008780Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel, pomalidomide, bortezomib, dexamethasone and daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Mar 2020; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucelpomalidomidebortezomibdexamethasonedaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2020-06-08_008780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-08_008780.